Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ocrelizumab,Hyaluronidase
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Ocrevus Zunovo as First Twice-a-Year Subcutaneous Injection for MS
Details : Ocrevus Zunovo (ocrelizumab-hyaluronidase) is a humanised mAb-enzyme designed to target CD20-positive B cells, approved for the treatment of multiple sclerosis.
Brand Name : Ocrevus Zunovo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 13, 2024
Lead Product(s) : Ocrelizumab,Hyaluronidase
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche’s OCREVUS Subcutaneous Admin Approved as Twice-a-Year Injection for MS
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, approved as a subcutaneous injection, for the treatment of multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 25, 2024
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche’s Subcutaneous OCREVUS Shows Strong One-Year Results in MS Patients
Details : Ocrevus (ocrelizumab) is a twice-yearly subcutaneous injection designed to target CD20-positive B cells for treating progressive and relapsing multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 17, 2024
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 13, 2023
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 26, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCREVUS (ocrelizumab) data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS).
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 19, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ocrevus (Ocrelizumab) data will show significant benefit on slowing disease activity and progression in patients with treatment-naïve early-stage relapsing-remitting multiple sclerosis (RRMS).
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 18, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Analysis demonstrated positive effects of OCREVUS on cognition, with 70% of patients having improved cognition, as measured with SDMT. Clinically meaningful improvement was observed in 34% of patients treated with OCREVUS and worsening in 30% of patients...
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 04, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Genentech
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting
Details : OCREVUS (ocrelizumab), a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 25, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Genentech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCREVUS resulted in a 35% reduction in the risk of patients with RMS needing a walking aid over seven and a half years compared with patients who switched from interferon beta-1a to OCREVUS after the 96-week double-blind period.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 13, 2021
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?